These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 10193713

  • 1. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
    Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, Wolf RA.
    J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
    [Abstract] [Full Text] [Related]

  • 2. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
    Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M.
    J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
    Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L.
    Circulation; 1995 Feb 01; 91(3):691-7. PubMed ID: 7828295
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
    Kostis JB, Vachharajani NN, Hadjilambris OW, Kollia GD, Palmisano M, Marino MR.
    J Clin Pharmacol; 2001 Sep 01; 41(9):935-42. PubMed ID: 11549097
    [Abstract] [Full Text] [Related]

  • 10. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN.
    Circulation; 1999 May 25; 99(20):2658-64. PubMed ID: 10338459
    [Abstract] [Full Text] [Related]

  • 11. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
    Blanchet M, Sheppard R, Racine N, Ducharme A, Curnier D, Tardif JC, Sirois P, Lamoureux MC, De Champlain J, White M.
    Am Heart J; 2005 May 25; 149(5):938.e1-7. PubMed ID: 15894946
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
    Hope S, Brecher P, Chobanian AV.
    Am J Hypertens; 1999 Jan 25; 12(1 Pt 1):28-34. PubMed ID: 10075381
    [Abstract] [Full Text] [Related]

  • 13. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
    Carraway JW, Park S, McCune SA, Holycross BJ, Radin MJ.
    J Cardiovasc Pharmacol; 1999 Mar 25; 33(3):451-60. PubMed ID: 10069682
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
    Riegger GA, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, von Behren V, George M, Arens H.
    Circulation; 1999 Nov 30; 100(22):2224-30. PubMed ID: 10577995
    [Abstract] [Full Text] [Related]

  • 20. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL.
    J Hum Hypertens; 2010 Feb 30; 24(2):93-103. PubMed ID: 19458624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.